KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 121 filers reported holding KALA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,000 | -50.0% | 6,000 | 0.0% | 0.00% | – |
| Q2 2022 | $2,000 | -75.0% | 6,000 | 0.0% | 0.00% | – |
| Q1 2022 | $8,000 | +14.3% | 6,000 | 0.0% | 0.00% | – |
| Q4 2021 | $7,000 | -56.2% | 6,000 | 0.0% | 0.00% | – |
| Q3 2021 | $16,000 | -50.0% | 6,000 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $32,000 | -100.0% | 6,000 | -50.0% | 0.00% | 0.0% |
| Q1 2021 | $80,880,000 | +197168.3% | 12,000 | +100.0% | 0.00% | 0.0% |
| Q4 2020 | $41,000 | +78.3% | 6,000 | +100.0% | 0.00% | 0.0% |
| Q3 2020 | $23,000 | – | 3,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |